Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170005/S006

Abbott RealTime IDH2

Abbott Molecular, Inc. · Decision date May 28, 2026

FDA DECISIONP170005/S006

What did the FDA decide?

FDA records P170005/S006 as a supplement to PMA P170005, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 28, 2026.

FDA approval order statement

implementation of manufacturing changes
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Medical Genetics
Decision date
May 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170005/S006
Regulatory pathway
PMA supplement
Product code
OWD
Decision code
OK30
Decision date
May 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170005/S006 received

    Application receipt date recorded by FDA.

  2. P170005/S006 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P170005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170005

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Molecular, Inc.PMA supplementMar 20, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
RochePMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Molecular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1300 E Touhy Ave., Des Plaines, IL, 60018

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records